The Omnicell Blog
The pharmacy world is changing fast. The emergence of pharmacy intelligence, predictive analytics, and increasing demand for a complete end-to-end solution means healthcare leaders must innovate to meet both new medication management challenges (COVID-19) and old (diversion, patient safety, and rising costs).
The Omnicell Blog is the leading source for pharmacy information on emerging trends, successful best practices, and ideas and insights to help pharmacies digitally transform to lower cost and improve patient safety.
ASHP Midyear 2022: Partnering for Optimized Pharmacy Outcomes
We've missed connecting with our pharmacy and healthcare colleagues in person, and can't wait to see you In Las Vegas to share the new technology, insights, and services that are addressing the biggest challenges in medication management.
IV Robotics and the Latest USP Revisions
The U.S. Pharmacopeia (USP) published revisions to the general chapters on compounding Nonsterile <795> and Sterile <797> preparations, including robotic technology for the very first time. The latest revisions, which take effect November 1, 2023, exempt some robotic devices from surface sampling after every batch of Category 3 compounded sterile products (CSPs), and instead allow users of self-enclosed robotic devices to surface sample once per day. Sterile compounding is one of the most labor-intensive and risky areas of pharmacy. IV robotics have demonstrated proven benefits for safe, efficient sterile compounding for over 15 years, but market adoption has been slow.
Omnicell Compliance Week 2022: Integrity Inspires
Omnicell is celebrating its third Annual Compliance Week from November 7-11. Of note, this year also marks Omnicell's 30th anniversary. We have encouraged all of our employees to reflect upon how integrity has played an integral role in the growth of Omnicell throughout its 30-year history and how it will continue to be vital to every aspect of the company's future. We recognize our company would not be what it is today without integrity, and it remains an integral part of our continued success. In that spirit, our theme for Compliance Week 2022 is Integrity Inspires.
Simplifying Medication Management Allows Nurses to Focus More on Patient
Simplifying medication retrieval and administration workflow allow nurses to focus on the patient, not the technology. When Omnicell partnered with Oracle Cerner for interoperability between the EHR and the XT Automated Dispensing System, the result was improved waste compliance, near 100 percent visibility of potential transaction discrepancies, and time savings for nursing and pharmacy.
Omnicell Unveils Specialty Pharmacy Services in Summer 2022 Release
Omnicell’s launch of Specialty Pharmacy Services moves the company beyond acute care to provide a portfolio of solutions that truly enables us to help customers transform medication management from inpatient to outpatient, from the bedside to the home.
The Inflation Reduction Act: The Impact of Medicare Negotiation of Prescription Drug Prices on Hospitals and Health Systems
In August, H.R. 5376, the Inflation Reduction Act of 2022 (IRA), was passed via partisan votes by both chambers of Congress and signed into law by President Joe Biden. Senate Majority Leader Chuck Schumer (D-N.Y.) described the $739 billion climate, tax, and health bill “as one of the defining legislative feats of the twenty-first century,” and Biden similarly touted the IRA as “one of the most significant laws in our history.” While its climate change provisions captured top billing, the IRA is also arguably the most impactful health legislation since the Patient Protection and Affordable Care Act of 2010.
NASP 2022 Reveals a Pharmacy Landscape Shifting to Specialty
The 2022 NASP (National Association of Specialty Pharmacy) Annual Meeting and Expo illustrated how the continued growth and complexity of specialty medications is impacting the pharmaceutical industry. The event also provided attendees with several strategies to address recent challenges including labor shortages, digital transformation, and 340B administration.
Recent Developments Underscore Why 340B Providers Should Quickly Turn to Congress to Break Contract Pharmacy Impasse
October will be critical in the ongoing dispute over the scope of the 340B contract pharmacy program. The U.S. Court of Appeals for the District of Columbia Circuit has scheduled oral arguments on Oct. 24 in Novartis and United Therapeutics’ consolidated cases against the federal government.
Nursing Labor Shortage: A Next-Gen Perspective
For the twentieth year in a row, nursing has been ranked as the most trusted profession. But the stressors of COVID-19 revealed burnout and job dissatisfaction that too many nurses experience. In a recent McKinsey survey, nearly 30 percent of responding RNs indicated they were likely to leave their role in direct patient care.
Key Takeaways from New Medicare Law and Its Implications for 340B Stakeholders
Significant health care policy changes are rare in Washington, D.C., and this is especially so for drug pricing, where advocates have been fighting for over 30 years to let Medicare negotiate pharmaceutical prices. Learn from new takeaways about a new Medicare Law and its impact on 340B stakeholders.
The views and opinions expressed in this blog are those of the authors and do not necessarily reflect the official policy or position of any other agency, organization, employer or company. Assumptions made in the analysis are not reflective of the position of any entity other than the author(s). These views are always subject to change, revision, and rethinking at any time and may not be held in perpetuity.